Premium
GATA1 mutation analysis and molecular landscape characterization in acute myeloid leukemia with trisomy 21 in pediatric patients
Author(s) -
Panferova Agnesa,
Gaskova Marina,
Nikitin Eugenyi,
Baryshev Pavel,
Timofeeva Natalia,
Kazakova Anna,
Matveev Viktor,
Mikhailova Ekaterina,
Popov Alexander,
Kalinina Irina,
Hachatrian Lili,
Maschan Aleksey,
Maschan Michael,
Novichkova Galina,
Olshanskaya Yulia
Publication year - 2021
Publication title -
international journal of laboratory hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.705
H-Index - 55
eISSN - 1751-553X
pISSN - 1751-5521
DOI - 10.1111/ijlh.13451
Subject(s) - gata1 , sanger sequencing , myeloid leukemia , mutation , multiplex ligation dependent probe amplification , amplicon , cancer research , trisomy , biology , npm1 , microbiology and biotechnology , genetics , gene , exon , karyotype , polymerase chain reaction , chromosome , transcription factor
Accurate detection of GATA1 mutation is highly significant in patients with acute myeloid leukemia (AML) and trisomy 21 as it allows optimization of clinical protocol. This study was aimed at (a) enhanced search for GATA1 mutations; and (b) characterization of molecular landscapes for such conditions. Methods The DNA samples from 44 patients with newly diagnosed de novo AML with trisomy 21 were examined by fragment analysis and Sanger sequencing of the GATA1 exon 2, complemented by targeted high‐throughput sequencing (HTS). Results Acquired GATA1 mutations were identified in 43 cases (98%). Additional mutations in the genes of JAK/STAT signaling, cohesin complex, and RAS pathway activation were revealed by HTS in 48%, 36%, and 16% of the cases, respectively. Conclusions The GATA1 mutations were reliably determined by fragment analysis and/or Sanger sequencing in a single PCR amplicon manner. For patients with extremely low blast counts and/or rare variants, the rapid screening with simple molecular approaches must be complemented with HTS. The JAK/STAT and RAS pathway ‐ activating mutations may represent an extra option of targeted therapy with kinase inhibitors.